LifeScan today announced positive data from a study of real-world evidence supporting its Bluetooth-connected blood glucose meter.
Evidence from more than 55,000 people with diabetes demonstrated sustained improvements in readings in range. The analysis focuses on changes over 180 days. LifeScan published results in the peer-reviewed journal Diabetes Therapy.
The company’s OneTouch Bluetooth-connected blood glucose meter and mobile diabetes app provides simplicity, accuracy and trust, according to a news release.
“Blood glucose meters are used by over 95% of people with diabetes who monitor their glucose, making these real-world findings particularly relevant to tens of millions of people who rely on blood glucose meters to make decisions every day and to their healthcare providers,” said study co-author, Dr. Elizabeth Holt, head of global medical, clinical, and safety, LifeScan. “At the very least, the findings from this study should prompt people with either type 2 or type 1 diabetes to discuss with their healthcare provider if and how they could benefit more from using a smart blood glucose meter and its companion mobile app.”
About the LifeScan study
The study aimed to understand if using the OneTouch Reveal mobile app with the OneTouch Verio Reflect meter supported sustained glycemic improvements. It evaluated the app and meter — synced via Bluetooth — over 180 days in people with type 1 and type 2 diabetes.
Real-world data demonstrated that the type 2 diabetes population saw sustained, clinically significant improvements. These improvements occurred when engaging in just one to two OneTouch Reveal mobile app sessions per week, LifeScan said. They performed one to two meter checks per day over 180 days.
Results included reduced mean glucose by 20 mg/dL and improved readings in range by 12%. Hyperglycemic readings also reduced by 12.2% in those with type 2 diabetes, LifeScan said.
The company said it saw similar glycemic outcomes in those with type 1 diabetes, too. However, LifeScan said the type 2 improvements registered as more clinically meaningful in fewer sessions each week.
Data also demonstrated the highest engagement with the app in its 65 years of age or older group. The number of hypoglycemic readings in that population came in low and fairly similar between both types of diabetes. That population experienced significant glycemic improvements, although the magnitude was not as high as it was in younger age groups.
